David Venables, PhD, is a serial biotechnology entrepreneur and leader currently serving as the CEO of Laverock Therapeutics, where they engineer next-generation programmable cell therapies. They have held various significant roles, including President of AskBio Europe during its acquisition by Bayer and CEO of Synpromics, leading it to become a market leader in gene control and synthetic promoter development. David's past experience includes leadership positions at companies like Nightstar Therapeutics, Anatara Therapeutics, and Intercell, and they are actively involved in several boards and as an Honorary Professor at the University of Edinburgh. With a PhD in Bioprocess Engineering from the University of Surrey, David is also an accomplished endurance athlete, having recovered from severe injuries sustained in a near-death accident.
This person is not in the org chart
This person is not in any teams
This person is not in any offices